

FINAL REGISTRATION REPORT

Part B

Section 10

Assessment of the relevance of metabolites in groundwater

Detailed summary of the risk assessment

Product code: FEL02

Product name(s): Cuprofix C/Cuprofix C Disperss

Chemical active substance(s):

Copper (Bordeaux mixture), 200 g/kg

Cymoxanil, 40 g/kg

Central Zone

Zonal Rapporteur Member State: Poland

CORE ASSESSMENT

(Art. 33 new authorization)

Applicant: UPL Holdings Coöperatief U.A.

Submission date: March 2023

MS Finalisation date: November 2023; April 2024

Version history

When	What
March 2023	Part B - Section 10 - Core Assessment, Version 01 of applicant
November 2023	Assessment by expert
April 2024	The final version of the RR after the commenting period

Table of Contents

10	Relevance of metabolites in groundwater	4
10.1	General information	4
10.2	Relevance assessment of metabolites	4
Appendix 1	Lists of data considered in support of the evaluation	5

10 Relevance of metabolites in groundwater

10.1 General information

Cymoxanil:

None of the Cymoxanil relevant soil metabolites (IN-U3204, IN-W3595, IN-JX915 and IN-KQ960) are predicted to occur in groundwater at concentrations above 0.1 µg/L (see dRR part B section 8.8.2.1). Assessment of the relevance of these metabolites according to the stepwise procedure of the EC guidance document SANCO/221/2000 – rev.10 is therefore not required.

Copper:

Copper is an element and therefore cannot be transformed into related metabolites or degradation products. Hence, it is not necessary to include further information.

10.2 Relevance assessment of metabolites

Please refer to Point 10.1.

Comment:

Copper is an element and therefore cannot be transformed into related metabolites. It is accepted

The relevance of the groundwater metabolite IN-K960 has already been assessed and the assessment agreed at EU level (see Final addendum to DAR of Cymoxanil, July-September 2008).

IN-KQ960 is not considered relevant as RMS does not expect IN-KQ960 to exceed 0.1 µg/l in shallow groundwater even under more vulnerable conditions (*EFSA Scientific Report* (2008) 167, 1-116 Conclusion on the peer review of cymoxanil)

Appendix 1 Lists of data considered in support of the evaluation

No data are submitted with this section document.